These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16107928)

  • 1. Multiple risk factors in cardiovascular disease--fifth international symposium. 28-31 October 1999, Venice, Italy.
    Elisaf M
    IDrugs; 2000 Feb; 3(2):156-7. PubMed ID: 16107928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia.
    Ali YS; Linton MF; Fazio S
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):142-6. PubMed ID: 18316949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diabetes, dyslipidaemia and kidney diseases].
    Ceska R; Tesar V
    Vnitr Lek; 2008 May; 54(5):511-7. PubMed ID: 18630638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk factors and dementia.
    Fillit H; Nash DT; Rundek T; Zuckerman A
    Am J Geriatr Pharmacother; 2008 Jun; 6(2):100-18. PubMed ID: 18675769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B; Maes M; Zambon A
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid metabolism in chronic kidney disease: the role of statins in cardiovascular risk.
    Wanner C; Drechsler C; Krane V
    J Ren Nutr; 2007 Jan; 17(1):75-8. PubMed ID: 17198938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program).
    Hobbs FD; Gensini G; Mancini GB; Manolis AJ; Bauer B; Böhler S; Genest J; Feldman R; Harvey P; Jenssen TG; Metcalfe M; da Silva PM;
    Int J Cardiol; 2006 Jun; 110(2):242-50. PubMed ID: 16338012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Goal attainment for multiple cardiovascular risk factors in community-based clinical practice (a Canadian experience).
    Farahani P; Levine M
    J Eval Clin Pract; 2009 Feb; 15(1):212-6. PubMed ID: 19239605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New rules on hypolipidemic drug reimbursability in Italy].
    Paoletti R; Poli A
    Ital Heart J Suppl; 2001 Apr; 2(4):408-12. PubMed ID: 19397016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of dyslipidemia with statins in the patient with peripheral arterial disease.
    Blum AS
    Tech Vasc Interv Radiol; 2006 Jun; 9(2):50-5. PubMed ID: 17482100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated cardiovascular risk management for the future: lessons learned from the ASCOT trial.
    Volpe M; Tocci G
    Aging Clin Exp Res; 2005 Aug; 17(4 Suppl):46-53. PubMed ID: 16640173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardiovascular comorbidity in rheumatic disease. Does sex play a role?].
    Kung M; Störk S; Angermann CE
    Herz; 2005 Sep; 30(6):512-21. PubMed ID: 16170682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy.
    Avogaro A; Guida P; Giorda C; Mannucci E; Medea G; Comaschi M; Velussi M; Armienti G; Zucchetti R;
    Nutr Metab Cardiovasc Dis; 2007 Jan; 17(1):32-40. PubMed ID: 17174224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of statins on renal function.
    Agarwal R
    Am J Cardiol; 2006 Mar; 97(5):748-55. PubMed ID: 16490450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total cardiovascular risk management.
    Ritz E
    Am J Cardiol; 2007 Aug; 100(3A):53J-60J. PubMed ID: 17666199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dyslipidemia of chronic renal disease: effects of statin therapy.
    Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
    Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control.
    Schneider CA
    Curr Med Res Opin; 2006; 22 Suppl 2():S15-26. PubMed ID: 16914072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic kidney disease and statins].
    Matovinović MS
    Lijec Vjesn; 2006; 128(11-12):345-50. PubMed ID: 17212196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.